ArticleMethods in molecular biology (Clifton, N.J.)2026
Using 4-HPP and PP as Substrates to Assess Purified MIF and D-DT Tautomerase Activity and Inhibition.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human macrophage migration inhibitory factor (MIF) was first recognized as a lymphokine that prevents macrophage migration in vitro. However, subsequent studies have revealed that MIF also functions as a chemokine, recruiting monocytes, neutrophils, and lymphocytes to sites of inflammation. While the role of its homologue, D-dopachrome tautomerase (D-DT or MIF-2), is less well understood, it shares both unique and overlapping functions with MIF. Both MIF and D-DT exhibit tautomerase catalytic activity, with MIF's tautomerase active site being associated with health, but also the pathogenesis of various inflammatory conditions, autoimmune diseases, and cancers. In contrast, the role of D-DT's tautomerase active site in disease remains poorly understood. In this study, we present a method for evaluating the tautomerase activity and inhibition of recombinant purified MIF and D-DT, using 4-hydroxyphenylpyruvate (4-HPP) and phenylpyruvate (PP) as substrates. Although both substrates can be used to measure MIF tautomerase activity, 4-HPP is preferred, while PP is favored for D-DT, highlighting the distinct substrate specificities of the two enzymes.
Indexed as
Identifiers
42129116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.